Vitamin D insufficiency and diabetes risks

Current Drug Targets

Volumn 12, Issue 1, 2011, Pages 61-87

  Boucher, Barbara J ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Diabetes; Insufficiency; Insulin; Resistance; Secretion; Vitamin D

Indexed keywords

CALCIUM; COLECALCIFEROL; ERGOCALCIFEROL; VITAMIN D;

ARTICLE; AUTOIMMUNE DISEASE; CALCIUM ABSORPTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSAL ATTRIBUTION; DIABETES MELLITUS; DIET SUPPLEMENTATION; EPIDEMIC; HEALTH CARE COST; HUMAN; HYPERGLYCEMIA; INSULIN DEFICIENCY; INSULIN RELEASE; INSULIN RESISTANCE; METABOLIC DISORDER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOMALACIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RICKETS; RISK FACTOR; SUN EXPOSURE; SUNLIGHT; VITAMIN D DEFICIENCY;

AGING; ANIMALS; BIOLOGICAL MARKERS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENTS; FATTY LIVER; FOOD, FORTIFIED; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; NUTRITION POLICY; NUTRITIONAL REQUIREMENTS; RISK; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 78650861060     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945011793591653     Document Type: Article

References (258)

1. Milner RD, Hales CN. The role of calcium and magnesium in insulin secretion from rabbit pancreas studied in vitro. Diabetologia 1967; 3: 47-9.
2. 3 improves impaired glucose tolerance and insulin secretion in the vitamin D-deficient rat in vivo. Endocrinology 1986; 119: 84-90.
3. Labriji-Mestaghanmi H, Billaudel B, Gamier PE, Sutter BCJ. Vitamin D and pancreatic islet function. I. Time course for changes in insulin secretion and content during vitamin D deprivation and repletion. J Endocr Invest 1998; 11: 577-87.
4. Pittas A, Dawson-Hughes B, Li T, et al. Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care 2006; 29: 650-56.
5. Pal BR, Shaw NJ. Rickets resurgence in the United Kingdom: improving antenatal management in Asians. J Pediatr 2001; 139: 337-8.
6. Calvo MS, Whiting SJ, Barton CN. Vitamin D intake: a global perspective of current status. J Nutr 2005; 135: 310-6. Review.
7. th ed; Oxford: Oxford University Press 2003; 12: pp. 317-59.
8. Holick MF. Evolution and function of vitamin D. Recent Results Cancer Res 2003; 164: 3-28.
9. Engelsen O, Brustad M, Aksnes L, Lund E. Daily duration of vitamin D synthesis in human skin with relation to latitude, total ozone, altitude, ground cover, aerosols and cloud thickness. Photochem 2005; 81: 287-90.
10. Ekpe J. The Chemistry of light: the life and work of Theobald Adrian Palm (1848-1928). J Med Biogr 2009; 17: 155-60.
11. Gibbs DD. Rickets and the crippled child: an historical perspective. J R Soc Med 1994; 87: 729-32.
12. Hutchinson HS, Shah SJ. The aetiology of rickets, early and late. QJM 1921; 15: 167-94.
13. Holick MF. The vitamin D deficiency pandemic and consequences for nonskeletal health: mechanisms for action. Mol Aspects Med 2008; 29: 361-8.
14. Janssens W, Bouillon R, Claes B, et al. Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D binding gene. Thorax 2010; 65: 215-20.
15. Fichna M, Zurawek M, Januszkiewicz-Lewandowska D, et al. Association of the CYP27B1 C(-1260)A polymorphism with autoimmune Addison's disease. Exp Endocrinol Diab 2010; 118: 544-9.
16. 3 is unaffected. Results from a general population study in Goteborg Sweden. (The WHO MONICA Project). Eur J Clin Nutr 1995; 49: 440-7.
17. Wang S. Epidemiology of vitamin D in health and disease. Nutr Res Rev 2009; 22: 188-203.
18. Lundgren S, Carling T, Hjalm G, et al. Tissue distribution of human gp330/megalin, a putative Ca(2+) sensing protein. J Histochem Cytochem 1997; 45: 383-92.
19. 3. PNAS 2001; 98: 13895-900.
20. Liu W, Yu WR, Carling T, et al. Regulation of gp330/megalin expression by vitamins A and D. Eur J Clin Invest 1998; 28: 100-7.
21. Gressner OA, Lahme B, Gressner AM. Gc-globulin (vitamin D binding protein) is synthesized and secreted by hepatocytes and internalized by hepatic stellate cells through Ca(2+)-dependent interaction with the megalin/gp330 receptor. Clin Chem Acta 2008; 390: 28-37.
22. McGrath JJ, Saha S, Burns TH, Eyles DW. A systematic review of the association between single nucleotide polymorphisms and 24- hydroxyvitamin D concentrations. J Steroid Biochem Mol Biol 2010;[Epub ahead of print].
23. Zhao G, Simpson RU. Membrane localization, Caveolin-3 association and rapid actions of vitamin D receptor in cardiac myocytes. Steroids 2010; 75: 555-9.
24. Norman AW. Minireview: Vitamin D receptor: new assignments for an already busy receptor. Endocrinology 2006; 147: 5542-8.
25. Mizwicki MT, Norman AW. The vitamin D sterol-vitamin D receptor ensemble model offers unique insights into both genomic and rapid-response signalling. Sci Signal 2009; 75: re4, review.
26. McCullough ML, Bostick RM, Mayo TL. Vitamin D gene pathways polymorphisms and risk of colorectal, breast and prostate cancer. Ann Rev Nutr 2009; 29: 111-32.
27. 3. Endocrinology 1997; 138: 2233-40.
28. Awumey EM, Mitra DA, Hollis BW, Kumar R, Bell NH. Vitamin D metabolism is altered in Asian Indians in the southern United States: a clinical research centre study. J Clin Endocrinol Metab 1998; 83: 168-73.
29. Peacey SR, Wright D, Harries MJ. Failure to normalize parathyroid hormone during treatment of vitamin D deficiency in Asian patients. Clin Endocrinol 2004; 61: 603-6.
30. Ogunkolade BW, Boucher BJ, Bustin SA, et al. Vitamin D metabolism in peripheral blood mononuclear cells is influenced by chewing "Betel Nut" (Areca catechu) and vitamin D status. J Clin Endocrinol Metab 2006; 91: 2612-7.
31. Wareham NJ, Franks PW, Harding AH. Establishing the role of gene-environment interactions in the etiology of type 2 diabetes. Endocrinol Metab Clin North Am 2002; 31: 553-66.
32. Carlberg C, Seuter S. A genomic perspective on vitamin D signalling. Anticancer Res 2009; 29: 3485-93.
33. Hitman GA, Mannan N, McDermott MF, Aganna E, Hales CN, Boucher BJ. Vitamin D polymorphisms influence insulin secretion in Bangladeshi Asians. Diabetes 1998; 47: 688-90.
34. Ogunkolade BW, Boucher BJ, Prahl JM, et al. Vitamin D receptor (VDR) mRNA and VDR protein levels in relation to vitamin D status, insulin secretory capacity, and VDR genotype in Bangladeshi Asians. Diabetes 2002; 51: 2294-300.
35. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009; 32(Suppl 1): S62-67.
36. Olabi B, Bhopal R. Diagnosis of diabetes using the oral glucose tolerance test. Brit Med J 2009; 339: 1268-9.
37. No author lised. A change of units for HbA1c. Drug and Ther Bull 2010; 48: 23-4.
38. Gomez-Huelgas M, Bernal-Lopez MR, Mancera J, Tinahones FJ. HbA1c for diagnosis. Are we ready? Diab Med 2010; 27: 367-9.
39. Zhang Q, Ames JM, Smith RD, Baynes JW, Metz TO. A perspective on the Maillard reaction and the analysis of protein glycation by mass spectrometry: probing the pathogenesis of chronic disease. J Proteome Res 2009; 8: 754-69.
40. Jarrett RJ, Keen H, McCartney M, Fuller JH, Hamilton PJ, Rose G. Glucose tolerance and blood pressure in two population samples: their relation to diabetes mellitus and hypertension. Int J Epidemiol 1978; 7: 15-24.
41. Larkins K. Get the facts right. Balance 2010; 233: 39-42.
42. Holman RR, Paul SK, Bethel MA, Neil HA, Mathews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008; 359(15): 1565-76.
43. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. New Eng J Med 2008; 359: 1565-76 & 1577-89.
44. Kilpatrick ES, Rigby AS, Atkin SL. The Diabetes Control and Complications Trial: the gift that keeps giving. Nat Rev Endocrinol 2009; 5: 537-45.
45. Genuth S. The UKPDS and its global impact. Diabet Med 2008; 25(Suppl 2): 57-62.
46. Borchers AT, Uibo R, Gershwin ME. The geoepidemiology of type 1 diabetes. Autoimm Rev 2010; 9: A355-65.
47. Papandreou D, Malindretos P, Karabouta Z, Rousso I. Possible health implications and low vitamin D status during childhood and adolescence: an updated mini review. Int J Endocrinol 2010;[Epub ahead of print].
48. Report of the National Commission on Diabetes to the Congress of the United States. Vol 1. The long-range plan to combat diabetes. DHEW Pub. No(NIH) 76-1018:1 1976.
49. Hauner H. Diabetesepidemie und Dunkelziffer. In: Deutsche Diabetes Union, ed. Deutscher Gesundheitsbericht Diabetes Kircheim, Mainz 2007; pp. 7-12. www.springerlink.com/content/ m001524034808822/
50. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 12047-53.
51. Balarajan R. Ethnicity and variations in mortality from coronary heart disease. Health Trends 1996; 28: 45-51.
52. Boucher BJ. Strategies for reduction in the prevalence of NIDDM; the case for a population-based approach to the development of policies to deal with environmental factors in its development. Diabetologia 1995; 8: 1125-9.
53. Todd JA. The genetics of Diabetes. Chapter 12.11.2. In: Warrell DA, Cox TM, Firth JD, Benz EJ, Eds. The Oxford Textbook of Medicine, Oxford: Oxford University Press 2003; pp. 360-1.
54. Gloyn AL. RD Lawrence Lecture 2009. Old genes, new tricks: learning about blood glucose regulation from naturally occurring genetic variation in humans. Diabetic Med 2009; 26: 1083-9.
55. Gamble DR, Taylor KW. Seasonal incidence of diabetes mellitus. Brit Med J 1969; 3: 631-3.
56. Liu PT, Stenger S, Wenzel L, et al. Toll-like receptor triggering of a vitaminD-mediated human antimicrobial response. Science 2006; 311: 1770-3.
57. Huynh T, Greer RM, Nyunt O, et al. The association between ketoacidosis and 25(OH)-vitamin D levels at presentation in children with type 1 diabetes. Pediatr Diabetes 2009; 10: 38-43.
58. Boucher BJ. Inadequate vitamin D status: does it contribute to the disorders comprising syndrome 'X'? Brit J Nutr 1998; 79: 315-27.
59. Dhawan J, Bray CL, Warburton R, Ghambhir DS, Morris J. Insulin resistance, high prevalence of diabetes, and cardiovascular risk in immigrant Asians. Genetic or environmental effect? Br Heart J 1994; 72: 413-21.
60. Dandona P, Fonseca V, Menon RK. Vitamin D deficiency and the endocrine pancreas. Diabetologia 1986; 29: 468-9.
61. Davidson HV, Rhodes CJ, Hutton JC. Intraorganellar calcium and pH control proinsulin cleavage in the pancreatic beta cell via two distinct site-specific endopeptidases. Nature 1988; 333: 93-6.
62. Frankel BJ, Heldt AM, Grodsksy GM. Vitamin D deficiency inhibits pancreatic secretion of insulin. Science 1980; 209: 823-5.
63. Kadowski S, Norman AW. Dietary vitamin D is essential for normal insulin secretion from the perfused rat pancreas. J Clin Invest 1984; 73: 759-66.
64. Nyomba BL, Bouillon R, De Moor P. Influence of vitamin D status on insulin secretion and glucose tolerance in the rabbit. Endocrinology 1984; 115: 191-7.
65. 3 pretreatment. Diabete et Metabolisme 1989; 15: 85-7.
66. Levy J, Gavin JR, Sowers JR. Diabetes mellitus: a disease of abnormal cellular calcium metabolism? Am J Med 1994; 96: 260-3.
67. Gedik O, Akalan S. Effects of vitamin D deficiency and repletion on insulin and glucagon secretion in man. Diabetologia 1986; 29: 142-5.
68. Orwoll E, Riddle M, Prince M. Effects of vitamin D on insulin and glucagon secretion in non-insulin-dependent diabetes mellitus. Am J Clin Nutr 1994; 59: 1083-7.
69. Borkar VV, Verma S, Bhalla A. Low levels of vitamin D in North Indian children with newly diagnosed type 1 diabetes. Pediatr Diabetes 2010; 11: 345-50.
70. 3 in patients with newly diagnosed type 1 diabetes. Horm Metab Res 2005; 37: 680-3.
71. Lind L, Pollare T, Hvarfner A, Lithell H, Sorensen OH, Ljunghall S. Long-term treatment with active vitamin D (alphacalcidol) in middle-aged men with impaired glucose tolerance. Effects on insulin secretion and sensitivity, glucose tolerance and blood pressure. Diabetes Res 1989; 11: 141-7.
72. Lind L, Lithell H, Skarfors E, Wilde L, Ljunghall S. Reduction of blood pressure by treatment with alphacalcidol. A double-blind, placebo-controlled study in subjects with impaired glucose tolerance. Acta Med Scand 1998: 22: 211-7.
73. Mak R. Amelioration of hypertension and insulin resistance by 1,25-dihydroxycholecalciferol in hemodialysis patients. Pediatr Nephrol 1992; 6: 345-8.
74. 3 corrects insulin and lipid abnormalities in uremia. Kidney Int 1998; 53: 1363-7.
75. Mak RH. (a) Intravenous 1,25 dihydroxycholecalciferol corrects glucose intolerance in haemodialysis patients. Kidney International 1992; 41: 1049-54.
76. Mak RH (b) Amelioration of hypertension and insulin resistance by 1,25-dihydroxycholecalciferol in hemodialysis patients. Pediatric Nephrol 1992; 6: 345-8.
77. Kautsky-Willer A, Pacini G, Barnas U, et al. Intravenous calcitriol normalizes insulin sensitivity in uremic patients. Kidney International 1995; 47: 200-6.
78. 3 users in a haemodialysis population. Nephrol Dial Transplant 2004; 19: 179-84.
79. Johnson MD, Nader NS, Weaver AL, Singh R, Kumar S. Relationships between 25-hydroxyvitamin D levels and plasma glucose and lipid levels in pediatric outpatients. J Pediatr 2010; 156: 444-9.
80. Fahlen M, Oden A, Bjorntorp P, Tibblin G. Seasonal influence on insulin secretion in man. Clin Sci 1971; 41: 453-8.
81. Christau B, Kroman H, Andersen OO, et al. Incidence, seasonal and geographical patterns of juvenile-onset insulin-dependent diabetes mellitus in Denmark. Diabetologia 1977; 13: 281-4.
82. Soltesz G, Patterson CC, Dahlquist G. EURODIAB Study Group. World-wide childhood type 1 diabetes incidence - what can we learn from epidemiology? Pediatr Diabetes 2007; 8(Suppl 6): 6-14.
83. Boucher BJ, Mannan N, Noonan K, Hales CN, Evans SJW. Glucose intolerance and impairment of insulin secretion in relation to vitamin D deficiency in East London Asians. Diabetologia 1995; 38: 1239-45.
84. Feskens EJ, Virtanen SM, Räsänen L, et al. Dietary factors determining diabetes and impaired glucose tolerance. A 20-year follow-up of the Finnish and Dutch cohorts of the Seven Countries Study. Diabetes Care 1995; 18: 1104-12.
85. Feskens EJ, Bowles CH, Kromhout D. Inverse association between fish intake and risk of glucose intolerance in normoglycaemic elderly men and women. Diabetes Care 1991; 14: 935-41.
86. Baynes K, Boucher BJ, Feskens EJM, Kromhout D. Vitamin D, glucose tolerance and insulinaemia in elderly men Diabetologia 1997; 40: 344-7.
87. Forouhi NG, Luan J, Cooper A, Boucher BJ, Wareham NJ. Baseline serum 25-hydroxyvitamin D is predictive of future glycemic status and insulin resistance: The Medical Research Council Ely Prospective Study 1990-2000. Diabetes 2008; 57: 2619-25.
88. Liu E, Meigs JB, Pittas A, et al. Plasma 25-hydroxyviatmin D is associated with markers of the insulin resistant phenotype in nondiabetic adults. J Nutr 2009; 139: 329-34.
89. Kocian J. Diabetic osteopathy. Favourable effect of treatment of osteomalacia with vitamin D and calcium on high blood glucose levels (In Czech). Vnitrni Lekarstvi 1992; 38: 353-6.
90. 3 on insulin secretion. Diabetes 1981; 30: 382-6.
91. Ljunghall S, Lind L, Lithell H, et al. Treatment with one-alpha-hydroxycholecalciferol in middle-aged men with impaired glucose tolerance - a prospective randomized double-blind study. Acta Medica Scandinavica 1987; 222: 361-7.
92. Kumar S, Davies M, Zakaria Y, et al. Improvement in glucose tolerance and beta-cell function in a patient with vitamin D deficiency during treatment with vitamin D. Postgrad Med J 1994; 70: 440-3.
93. Harrison SA. New treatments for non alcoholic fatty liver disease. Curr Gastroenterol Rep 2006; 8: 21-9.
94. 3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2007; 17: 517-24.
95. 3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovascular Dis 2007; 17: 517-24.
96. The EURODIAB Substudy 2 Study Group. Vitamin D supplement in early childhood and risk for type 1 (insulin-dependent) diabetes mellitus. The EURODIAB Substudy 2 Study Group. Diabetologia 1999; 42: 51-4.
97. Stene LC, Joiner G, Norwegian Childhood Diabetes Study Group. Use of cod liver oil during the first year of life is associated with lower risk of childhood-onset type 1 diabetes: a large population-based, case-control study. Am J Clin Nutr 2003; 78: 1128-34.
98. Stene LC, Ulriksen J, Magnus P, Joner G. Use of cod liver oil during pregnancy associated with lower risk of type 1 diabetes in the offspring. Diabetologia 2000; 43: 1093-8.
99. Hyppönen E, Läärä E, Reunanen A, Järvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth cohort. Lancet 2001; 358: 1500-3.
100. Helgason T, Danielson R, Thomson AV. Incidence and prevalence of type 1 (insulin-dependent) diabetes mellitus in Icelandic children 1970-1989. Diabetologia 1993; 35: 880-3.
101. Ayer P. Rock and roll ghost town (Iceland). In: Falling off the Map: Some Lonely Places in the World, pp. 77-94. Reading: Black Swan, 1991.
102. Olafsdottir AS, Thorsdottir I, Wagner KH, Elmadfa I. Polyunsaturated fatty acids in the diet and breast milk of lactating Icelandic women with traditional fish and cod-liver oil consumption. Ann Nutr Metab 2006; 50: 270-6.
103. Lamberg-Allardt C. Vitamin D and the Finnish experience. Proceedings of the Rank Forum on Vitamin D 2009. Brit J Nutr 2010; in press.
104. Välimäki VV, Löyttyniemi E, Välimäki MJ. Vitamin D fortification does no resolve hypovitaminosis D in young Finnish men. Eur J Clin Nutr 2007; 61: 493-7.
105. Piirainen T, Laitinen K, Isolauri E. Impact of national fortification of fluid milks and margarines with vitamin D on dietary intake and serum25-hydroxyvitamin D concentration in 4-year-old children. Eur J Clin Nut 2007; 61: 123-8.
106. McKinney PA, EURODIAB Seasonality of Birth Group. Europe and diabetes. Diabetologia 2001; 44(Suppl 3): B67-74.
107. Javaid MK, Crozier SR, Harvey NC, et al. Maternal vitamin D status during pregnancy and childhood bone mass at 9 years: a longitudinal study. Lancet 2006; 367: 36-43.
108. Sayers A, Tilling K, Boucher BJ, Noonan K, Tobias JH. Predicting ambient ultraviolet from routine meteorological data; its potential use as an instrumental variable for vitamin D status in pregnancy in a longitudinal birth cohort in the UK. Int J Epidemiol 2009; 38: 1681-8.
109. th Jan 2010].
110. Barker DJP, Hales CN, Fall CHD, Osmond C, Phipps K, Clark PMS. Type2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia 1993; 36: 62-7.
111. Soltesz G, Patterson CC, Dahlquist G, EURODIAB Study Group. Worldwide childhood type 1 diabetes incidence - what can we learn from epidemiology? Pediatr Diabetes 2007; 8(Suppl 6): 6-14.
112. Yamshchikov AV, Desai NS, Blumberg HM, Ziegler TR, Tangpricha V. Vitamin D for treatment and prevention of infectious diseases: a systematic review or randomized controlled trials. Endoc Pract 2009; 15: 438-49.
113. Vaiserman AM, Khalangot MD, Cartensen B, et al. Seasonality of birth in adult type 2 diabetic patients in three Ukrainian regions. Diabetologia 2009; 52: 2665-7.
114. Maria RK, Rathee S, Lata V, Mudgli S. Effects of vitamin D supplementation in pregnancy. Gynecol Obstet Invest 1981; 12: 155-61.
115. Nap RC, Hazewinkel HA. Growth and development in the dog in relation to nutrition; a review. Vet Q 1994; 16: 50-9.
116. Desai M, Petrie CJ, Wang CL, O'Connell DA, Hales CN. Effects of maternal and early vitamin D deficiency on glucose and lipid metabolism in rat offspring. Diabetic Medicine 1997; 14(Suppl): S38.
117. th Vitamin D Workshop, 2009. Bruges, Belgium. www.vitamind.uct.edu/14thprogram.pdf
118. 3, apolipoprotein A-1 and high density lipoprotein cholesterol. Arterioscler Thromb 1992; 22: 671-4.
119. Chiu KC, Chug A, Go VL, Sad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 2004; 79: 820-5.
120. John WG, Noonan K, Mannan N, Boucher BJ. Hypovitaminosis D is associated with reductions in serum apolipoprotein A-1 but not with fasting lipids in British Bangladeshis. Am J Clin Nut 2005; 82: 517-22.
121. Grimes DS. Are statins analogues of vitamin D? Lancet 2006; 368: 83-6.
122. Rejnmark L, Vestergaard P, Heickendorff L, Mosekilde L. Simvastatin does not affect vitamin D status, but low vitamin D levels are associated with dyslipidemia: results from a randomised, controlled trial. Int J Endocrinol 2010; 2010: 957174.
123. Ford ES, Zhao G, Li C, Pearson WS. Serum concentrations of vitamin D and parathyroid hormone and prevalent metabolic syndrome among adults in the United States. J Diabetes 2003; 1: 296-303.
124. Mattila C, Knekt P, Mannisto S, et al. Serum 25-hydroxyvitamin D concentration and subsequent risk of T2DM. Diabetes Care 2007; 30: 2569-70.
125. Laaksonen MA, Kneki P, Rissanen RH, et al. The relative importance of modifiable potential risk factors of type 2 diabetes: a meat-analysis of two cohorts. Eur J Epidemiol 2009; [Epub ahead of print].
126. Knekt P, Laaksonen M, Mattila C, et al. Serum vitamin D and subsequent occurrence of type 2 diabetes. Epidemiology 2008; 19: 666-71.
127. Ginde AA, Scragg R, Schwartz RS, Camargo CA Jr. Prospective study of serum 25-hyrdroxyvitamin D level, cardiovascular disease mortality and all-cause mortality in older U.S. adults. J Am Geriatr Soc 2009; 7: 1595-603.
128. De Boer IH, Tinker LF, Connelly S, et al. Calcium plus vitamin D supplementation and the risk of incident diabetes in the Women's Health Initiative. Diabetes Care 2008; 31: 701-7.
129. Kirii K, Mizoue T, Iso H, et al. Calcium, vitamin D and dairy intake in relation to type 2 diabetes risk in a Japanese cohort. Diabetologia 2009; 52: 2542-50.
130. Pittas A, Harris SS, Stark PC, Dawson-Hughes B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in non diabetic adults. Diabetes Care 2007; 30: 980-6.
131. Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 2007; 92: 2017-29.
132. Major GC, Alarie F, Doré J, Phouttama S, Tremblay A. Supplementation with calcium + vitamin D enhances the beneficial effects of weight loss on plasma lipid and lipoprotein concentrations. Am J Clin Nutr 2007; 85: 54-9.
133. Major GC, Alarie F, Doré J, Tremblay A. Calcium plus vitamin D supplementation and fat mass loss in female very low-calcium consumers: potential link with a calcium-specific appetite control. Br J Nutr 2009; 101: 659-63 (see also correspondence in Br J Nutr 2009; 102: 1538-40).
134. Wareham NJ, Byrne CD, Carr C, Day NE, Boucher BJ, Hales CN. Glucose intolerance is associated with altered calcium homeostasis: a possible link between increased serum calcium and cardiovascular mortality. Metabolism 1997; 10: 1171-7.
135. Pitocco D, Crino A, Did Stasis E, et al. The effects of calcitriol and nicotinamide on residual pancreatic beta-cell function in patients with recent-onset Type 1 diabetes (IMDIAB XII). Diabet Med 2006; 23: 920-3.
136. Borissova AM, Tankova T, Kirilov G, Dakovska L, Kovacheva R. The effects of vitamin D on insulin secretion and peripheral insulin sensitivity in type 2 diabetic patients. Int J Clin Pract 2003; 57: 258-61.
137. Tuomilehto J, Knowler WC, Zimmet P. Primary prevention of non-insulin -dependent diabetes mellitus. Diabetes Metab 1992; 8: 339-53.
138. Rhodes CJ, Alarcon C. What beta cell defect could lead to hyperproinsulinaemia in NIDDM? Some clues from recent advances made in understanding the proinsulin-processing mechanism. Diabetes 1994; 43: 511-17.
139. Kitsou-Mylona I, Burns CJ, Squires PE, Persaud SJ, Jones PM. A role for the extracellular calcium-sensing receptor in cell-cell communication in pancreatic islets of Langerhans. Cell Physio Biochem 2008; 22: 557-66.
140. Leung PS. The physiology of a local renin-angiotensin system in the pancreas. J Physiol 2007; 580: 31-7.
141. Leung PS, Boucher BJ. The role of vitamin D in the modulation of the pancreatic renin-angiotensin system. In: 'Angiotensin Research progress. Miura H, Sasaki Y. Eds. Nova Science Publishers Inc. 2008; pp. 201-20.
142. Li YC, Kong J, Wei M, et al. 25Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110: 229-38.
143. Forman JP, Williams JS, Fisher ND. Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans. Hypertension 2010; 55: 1283-8.
144. The PEACE Trial Investigators: Angiotensin-Converting-Enzyme inhibition in stable coronary artery disease. New Eng J Med 2004; 351: 2058-68.
145. McGuire DK, Winterfield JR, Rytlewski JA, Ferranini E. Blocking the renin angiotensin-aldosterone system to prevent diabetes mellitus. Diab Vasc Dis Res 2008; 5: 59-66.
146. Tikellis C, Cooper ME, Thomas MC. Role of the renin-angiotensin system in the endocrine pancreas: implications for the development of diabetes. Int J Biochem Cell Biol 2006; 38: 737-51.
147. 3 suppresses high glucose-induced angiotensinogen expression in kidney cells by blocking the NF-{kappa}B pathway. Am J Physiol Renal Physiol 2009; 296: 212-8.
148. Paul M, Mehr AP, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2006; 86: 747-803.
149. Fiotti N, Altamura N, Orlando C, et al. Metalloproteineses-2, -9 and TIMP-1 expression in stable and unstable coronary plagues undergoing PCI. Int J Cardiol 2008; 127: 350-7.
150. Zhu XW, Price NM, Gilman RH, Gilman RH, Recarvarren S, Friedland JS. Multinucleate giant cells release functionally unopposed matrix metalloproteinase-9 in vitro and in vivo. J Infect Dis 2007; 196: 1076-9.
151. Tang QD, Wu PS, Hou YQ, et al. Plasma matrix metalloproteinases-2 and -9 levels are elevated in patients with acute coronary syndrome and coronary chronic total occlusion. Nan Fang Yi Da Xue Xue Bao 2009; 29: 1004-7.
152. Kai H, Ikeda H, Yasukawa H. Peripheral blood levels of matrix metalloproteinases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998; 32: 368-72.
153. Tetlow LC, Wooley DE. The effects of 1 alpha,25-dihyrdorxy-vitamin D(3) on matrix metalloproteinase and prostaglandin E(2) production by cells of the rheumatoid lesion. Arthritis Res 1999; 1: 63-70.
154. Timms PM, Mannan N, Hitman GA, et al. Circulating MMP, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders. QJM 2002; 95: 787-96.
155. 3 inhibits matrix metallatoproteinases induced by Mycobacterium tuberculosis infection. Immunology 2009; 127: 539-48.
156. Cheng S, Massaro JM, Fox CS, et al. Adiposity, Cardio-metabolic risks and vitamin D status: the Framingham Heart Study. Diabetes 2010; 59: 242-8.
157. Worstman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000; 72: 690-3.
158. Reis JP, von Muhlen D, Miller ER 3rd, Michos ED, Appel LJ. Vitamin D status and cardiometabolic risk factors in the United States adolescent population. Pediatrics 2009; [Epub ahead of print].
159. 3 inhibits uncoupling protein 2 expression in human adipocytes. FASEB J 2002; 16: 1808-10.
160. Wong KE, Szeto FL, Zhang W, et al. Involvement of the vitamin D receptor in energy metabolism: regulation of uncoupling proteins. Am J Physiol Endocrinol Metab 2009; 296: E820-8.
161. Bruno C, Fulford AD, Potts JR, et al. Serum markers of bone turnover are increased at six and 18 months after Roux-en-Y bariatric surgery: correlation with reduction in leptin. J Clin Endocrinol Metab 2010; 95: 159-66.
162. Aasheim ET, Bjorkman S, Sovik TT, et al. Vitamin status after bariatric surgery: a randomized study of gastric bypass and duodenal switch. Am J Clin Nutr 2009; 90: 15-22.
163. Walicka M, Czerwinski E, Tallulah M, Marcinowska-Suchowierska E. Influence of weight reduction on leptin concentration and bone mineral density in patients with morbid obesity before and 6 months after bariatric surgery. Endokrynol Pol 2009; 60: 97-102.
164. 3 through the down-regulation of telomerase. J Biol Chem 2004; 279: 53213-21.
165. Yamada O, Takanashi M, Ujihara M, Mizoguchi H. Down-regulation of telomerase activity is an early event of cellular differentiation without apparent telomeric DNA change. Lek Res 1998; 22: 711-7.
166. 3 concentrations are associated with longer leukocyte telomere length in women. Am J Clin Nutr 2007; 86: 1420-5.
167. Astrup AS, Tarnow L, Jorsal A, et al. Telomere length predicts all-cause mortality in patients with type 1 diabetes. Diabetologia 2010; 53: 45-8.
168. Foulis AK, Farquharson MA, Meager A. Immunoreactive alpha-interferon in insulin-secreting beta cells in type 1 diabetes mellitus. Lancet 1987; 19: 1423-7.
169. Toms GC, Baker P, Boucher BJ. The production of immuno-reactive alpha- and gamma-interferon by circulating mononuclear cells in type 1 diabetes. Diab Med 1991; 8: 547-50.
170. Planas P, Carrillo J, Sanchez A, et al. Gene expression profiles for the human pancreas and purified islets in Type 1 diabetes: new findings at clinical onset and in long-standing diabetes. Clin Exp Immunol 2009; 159: 23-44.
171. Skyler JS. Prediction and prevention of type 1 diabetes: progress, problems and prospects. Clin Pharmacol Ther 2007; 768-71.
172. Alhadj Ali M, Dayan CM. The importance of residual beta-cell preservation in type 1 diabetes. Br J Diabetes Vasc Dis 2009; 9: 248-53.
173. Fleming A. What will it take to get therapies approved for type 1 diabetes? Ann NY Acad Sci 2008; 1150: 25-31.
174. Stein MS, Wark JD. An update on the therapeutic potential of vitamin D analogues. Expert Opin Investig Drugs 2003; 12: 825-40.
175. Marshall TG. Vitamin D discovery outpaces FDA decision making. Bioessays 2008; 30: 173-82.
176. Waterhouse JC, Perez TH, Albert PJ. Reversing bacteria-induced vitamin D receptor dysfunction is key to autoimmune disease. Ann NY Acad Sci 2009; 1173: 757-65.
177. Mathieu C, Waer M, Casteels K, Laureys J, Bouillon R. Prevention of Type 1 diabetes in NOD mice by non hypercalcaemic doses of a new structural analogue of 1,25-dihydroxyvitamin D, KH1060. Endocrinology 1995; 136: 866-72.
178. Cantorna MT, Yu S, Bruce D. The paradoxical effects of vitamin D on type 1 mediated immunity. Mol Aspects Med 2008; 29: 369-75.
179. Hewison M, Burke F, Evans KN, et al. Extra-renal 25- hydroxyvitamin D-1alpha-hydroxylase in human health and disease. J Steroid Biochem Mol Biol 2007; 103: 316-21.
180. Boucher BJ. Comment on Vitamin D discovery outpaces FDA decision making". Bioessays 2008; 30: 508-9.
181. Evans KN, Bulmer JN, Kilby MD, Hewison M. Vitamin D and placental-decidual function. J Soc Gynecol Investig 2004; 11: 263-71.
182. Bolland MJ, Grey A, Reid IR. Time for a moratorium on vitamin D meta-analysis. Brit Med J 2009; 339: 987.
183. 3 supplementation on fractures and mortality in men and women living in the community. Randomized double blind controlled trial. Br Med J 2003; 326: 469-72.
184. Nagpal J, Pande JN, Bhartia A. A double-blind placebo-controlled trial of the short-term effect of vitamin D supplementation on insulin sensitivity in apparently healthy middle aged centrally obese men. Diabet Med 2009; 26: 19-27.
185. von Hurst PR, Stonehouse W, Coad J. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient - a randomized, placebo-controlled trial. Brit J Nut 2009; 28: 1-7.
186. Working Group of the Australia and New Zealand Bone and Mineral Society, Endocrine Society of Australia and Osteoporosis Australia. Vitamin D and adult bone health in Australia and New Zealand: a position statement. Med J Aust 2005; 182: 281-5.
187. Lips P. Which circulating level of 25-D is appropriate? J Steroid Biochem 2004; 89-90: 611-4.
188. Bischoff-Ferrari H. Vitamin D: What is an adequate vitamin D level and how much supplementation is necessary? Best Prac Res Clin Rheumatol 2009; 23: 789-95.
189. Hypponen E, Berry DJ, Wjst M, Power C. Serum 25-hydroxy-vitamin D and IgE - a significant but non-linear relationship. Allergy 2009; 64: 613-20.
190. 2 compared with HPLC: need for assay-specific decision limits and metabolite-specific assays. Ann Clin Biochem 2006; 43(Pt 1): 23-30.
191. Binkley N, Krueger D, Lensmeyer G. 25-hydroxyvitamin D measurement, 2009: a review for clinicians. J Clin Densitom 2009; 12: 417-27.
192. 3: a noninvasive tool for the assessment of vitamin D status. Anal Bioanal Chem 2008; 391: 229-38.
193. Mosekilde L. Vitamin D and the elderly. Clin Endocrinol 2005; 62: 265-81.
194. Boucher BJ, Mannan N, Cunningham J. Vitamin D status and bone mass in UK South Asian women. Bone 2007; 40: 1182.
195. Haberner JF, Kemper B, Potts JT Jr. Calcium-dependent intra-cellular degradation of parathyroid hormone: a possible mechanism for the regulation of hormone stores. Endocrinology 1975; 97: 431-41.
196. Beaulieu C, Kestekian R, Havrankova J, Gascon-Barre M. Calcium is essential in normalizing intolerance to glucose that accompanies vitamin D depletion in vivo. Diabetes 1993; 42: 35-43.
197. Gilchrest BA. Sun exposure and vitamin D sufficiency. Am J Clin Nutr 2008; 88: 570S-77S.
198. th edition of McCance and Widdowson's 'The Composition of Foods'. Pub. Royal Society of Chemistry. 1993.
199. Corless DF, Gupta SP, Sattar DA, Switala S, Boucher BJ. Vitamin D status in residents of an old people's home and long-stay patients. Gerontology 1979; 25: 350-5.
200. Corless D, Boucher BJ, Cohen RD, Beer M, Gupta SP. Vitamin D status in long-stay geriatric patients. Lancet 1975; 28: 1404-6.
201. Corless D, Gupta SP, Switala S, et al. Response of plasma 25- hydroxyvitamin D to ultraviolet irradiation in long-stay geriatric patients. Gerontology 1978; 25: 350-5
202. Barragry JM, France MW, Corless D, et al. Intestinal cholecalciferol absorption in the elderly and in younger subjects. Clin Sci Mol Med 1978; 58: 213-20.
203. Tsai KS, Heath H 3rd; Kumar R, Riggs BL. Impaired vitamin D metabolism with aging in women. Possible role in pathogenesis of senile osteoporosis. J Clin Invest 1984; 73: 1682-72.
204. Sergeev IN, Arkhapchev YP, Spireichev VB. Ascorbic acid effects on vitamin D hormone metabolism and binding in guinea pigs. J Nutr 1990; 120: 1185-90.
205. O'Hara-May J, Widdowson EM. Diets and living conditions of Asian boys in Coventry with and without signs of rickets. Brit J Nut 1976; 36: 23-6.
206. Roth J, Bonner-Weir S, Norman AW, Orci L. Immunohisto-chemistry of vitamin D dependent calcium binding protein in chick pancreas; exclusive localization in beta cells. Endocrinology 1982; 116: 2216-8.
207. McDermott MF, Ramachandran A, Aganna E, et al. Allelic variation in the vitamin D receptor influences susceptibility to IDDM in Indian Asians. Diabetologia 1997; 40: 971-5.
208. Lopez ER, Regulla K, Pani MA, Krause M, Usadel KH, Badenhoop K. CYP27B1 polymorphisms variants are associated with type 1 diabetes in Germany. J Steroid Biochem Mol Biol 2004; 89-90: 155-7.
209. Szathmary EJ. The effect of Gc genotype on fasting insulin level in Dogrib Indians. Human Genetics 1987; 75: 368-72.
210. Iyengar S, Hamman RF, Marshall JA, Majumder PP, Ferrell RE. On the role of vitamin D binding globulin in glucose homeostasis: Results from the San Luis Valley Diabetes Study. Genetic Epidemiology 1989; 6: 691-8.
211. Chowdhury TA, Boucher BJ, Hitman GA. Vitamin D and type 2diabetes: Is there a link? Primary Care Diabetes 2009; 3: 115-6.
212. Bivins R. "The English Disease" or "Asian Rickets"? Medical responses to postcolonial immigration. Bull Hist Med 2007; 81: 533-68.
213. Tahini AA, Ball A, Shepherd L, Rahim A, Jones AF, Bates A. The prevalence of vitamin D abnormalities in South Asians with type 2 diabetes mellitus in the UK. Int J Clin Practr 2009; 10: 1-5.
214. Mannan N, Boucher BJ, Vitamin D status and bone mass in UK British South Asian women. Bone 2007; 40: 1182.
215. Primary Vitamin D deficiency in children and Primary vitamin D deficiency in adults. Drug Ther Bull 2006; 44: 25-9.
216. Blum M, Dallai GE, Dawson-Hughes B. Body size and serum 25-hydroxy vitamin D response to oral supplements in healthy older adults. J Am Coll Nutr 2008; 27: 274-9.
217. Blum M, Doinikowski G, Seyoum E, et al. Vitamin D(3) in fat tissue. Endocrin 2008; 33: 90-4.
218. Hypponen E, Boucher BJ, Berry DJ, Power C. 25-hydroxyvitamin D, IGF-1 and metabolic syndrome at 45 years of age: a cross-sectional study in the 1958 British Birth Cohort. Diabetes 2008; 57: 298-305.
219. Jorde R, Saleh F, Figenschau Y, Kamycheva E, Haug E, Sundsfjorf J. Serum parathyroid hormone (PTH) levels in smokers and non-smokers. The fifth Tromsø study. Eur J Endocrinol 2005; 152: 39-45.
220. Metz AL, Walser MM, Olson WG. The interaction of dietary vitamin A and vitamin D related to skeletal development in the turkey poult. J Nutr 1985; 115: 929-35.
221. Selmi C, Tsuneyama K. Nutrition, geoepidemiology, and autoimmunity. Autoimmun Rev 2009; 9: A267-70.
222. Coyne T, Ibiebele TI, Baade PD, McClintock CS, Shaw JE. Metabolic syndrome and serum carotenoids: findings of a cross-sectional study in Queensland, Australia. Brit J Nutr 2009; 102: 1668-77.
223. Mora JR, Iwata M, von Andrian UH. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev 2008; 8: 685-98.
224. Chertow BS, Sivitz WI, Baranetsky NG, et al. Vitamin A palmitate decreases intravenous glucose tolerance in man. Acta Vitamino-logica et Enzymologica 1982; 4: 291-8.
225. Chertow BS, Driscoll HK, Goking NQ, Primerano D, Cordle MB, Mathews KA. Retinoid-X receptors and the effects of 9-cis-retinoic acid on insulin secretion from RINm5F cells. Metabolism 1997; 46: 656-60.
226. Chertow BS, Blaner WS, Rajan N, et al. Retinoic acid receptor, cytosolic retinol-binding and retinoic acid binding protein mRNA transcripts and proteins in rat insulin-secreting cells. Diabetes 1993; 42: 1109-14.
227. Chertow BS, Blaner WS, Baranetsky MG, et al. Effects of vitamin A deficiency and repletion ion rat insulin secretion in vivo and in vitro from isolated islets. J Clin Invest 1987; 79: 163-9.
228. Chertow BS, Baker GR. The effects of vitamin A on insulin release and glucose oxidation in isolated rat islets. Endocrinology 1978; 103: 1562-72.
229. Werner H, Weinstein D, Bentov I. Similarities and differences between insulin and IGF-1: structures, receptors and signalling pathway. Arch Physiol Biochem 2008; 114: 17-22.
230. Kjeldsen T, Andersen AS, Wiberg FC, et al. The ligand specificities of the insulin receptor and the insulin-like growth factor 1 receptor reside in different regions of a common binding site. Proc Natl Acad Sci USA 1991; 88: 4404-8.
231. Baxter RC. Insulin-like growth factor-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol Endocrinology Metab 2000; 278: E967-76.
232. Cruickshank JK, Heald AH, Anderson, et al. Epidemiology of the insulin-like growth factor system in three ethnic group. Am J Epidemiol 2001; 154: 504-13.
233. Guler HP, Zapg J, Froesch ER. Short-term metabolic effects of recombinant human insulin-like growth factor 1 in healthy adults. N Eng J Med 1987; 16: 137-40.
234. Heald AH, Siddals KW, Fraser W, et al. Low circulating levels of insulin-like growth factor binding protein-1 (IGFBP-1) are closely associated with the presence of macrovascular disease and hypertension in type 2 diabetes. Diabetes 2002; 51: 2629-36.
235. Sandhu MS, Gibson JM, Heald AH, Dunger DB, Wareham NJ. Low circulating IGF-ll concentrations predict weight gain and obesity in humans. Diabetes 2003; 52: 1403-08.
236. Capoluongo E, Pitocco D, Lulli P, Minucci A, Santonocito C, Manto A. Serum free IGF-1 and IGFBP-3 levels and blood pressure in patients affected with type-1 diabetes. Cytokine 2006; 34: 303-11.
237. Boucher BJ. Inverse correlation between serum free IGF-1 and IGFBP-3 levels and blood pressure in patients with type 1 diabetes by Capoluongo et al. Cytokine 2007; 37: 181-2.
238. 3-1alpha hydroxylase. J Clin Endocrinol Metab 2001; 86: 884-94.
239. 3-induced growth inhibition of human prostate cancer cells. Prostate 2005; 15: 9-19.
240. Duan C, Ren H, Gao S. Insulin-like growth factors (IGFs), IGF receptors and IGF-binding proteins: roles in skeletal muscle growth and differentiation. Gen Comp Endocrinol 2010; 167: 344-51.
241. Schernhammer ES, Hankinson SE, Hunter DJ, Blouin MJ, Pollak MN. Polymorphic variation of the -202 locus in IGFBP3; influence on serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risks. Int J Cancer 2003; 107: 60-4.
242. 3, the IGF-1 system, leptin, anthropometric and body composition variables in a healthy randomly selected population. Horm Metab Res 2004; 36: 48-53.
243. 3 in growth plate development. Endocrinology 2009; 150: 4024-32.
244. Zhou S, Leboff MS, Glowacki J. Vitamin D metabolism and action in human bone marrow stromal cells. Endocrinology 2010; 151: 14-22.
245. Alison MR. Stem cells in pathobiology and regenerative medicine. J Pathol 2009; 217: 141-3.
246. 2. Clin Chem Acta 2009; 404: 144-8.
247. 3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab 2008; 93: 677-81.
248. The DIPART (vitamin D individual patient analysis of randomized trials) group. Brit Med J 2010; 340: 139.
249. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannuci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation A meta-analysis of randomized controlled trials. JAMA 2005; 293: 2257-64.
250. Veith R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin. Nutr 1999; 69: 842-56.
251. Veith R, Bischoff-Ferrari H, Boucher BJ, et al. The urgent need to recommend an intake of vitamin D that is effective. Am J Clin Nutr 2007; 85: 649-50.
252. Männisto S, Smith-Warner SA, Spiegelman D, et al. Dietary carotenoids and risk of lung cancer in a pooled analysis of seven cohort studies. Cancer Epidemiol Biomarkers Prev 2004; 13: 40-8.
253. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Eng JMed 1996; 334: 1150-5.
254. Gallicchio L, Boyd K, Matanoski G, Tao XG, Chen L, Lam TK. Carotenoids and the risk of developing lung cancer: a systematic review. Am J Clin Nutr 2008; 88: 372-83.
255. Ma Y, Khalif AB, Yee YK, et al. Identification and characterization of noncalcemic, tissue-selective, nonsecosteroidal vitamin D receptor modulators. J Clin Invest 2006; 116: 892-904.
256. Spina CS, Tangpricha V, Uskovic M, Adorinic L, Maehr H, Holick MF. Vitamin D and cancer. Anticancer Res 2006; 26: 2515-24.
257. Torres PU. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease. J Ren Nutr 2006; 16: 253-8.
258. Pittas AG, Chung M, Trikalinos T, et al. Systematic review: Vitamin D and cardiometabolic outcomes. Ann Int Med 2010; 152: 307-14.